JG
SRNE

Joel Greenblatt’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Joel Greenblatt’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,928
Closed -$222K – 1123
2020
Q3 		$222K Sell
19,928
-12,764
-39% -$117K 0.01% 915
2020
Q2 		$205K Buy
+32,692
New +$125K 0.01% 961
2018
Q3 		– Sell
-130,783
Closed -$942K – 1046
2018
Q2 		$942K Sell
130,783
-34,664
-21% -$236K 0.01% 598
2018
Q1 		$852K Buy
165,447
+122,575
+286% +$872K 0.01% 634
2017
Q4 		$163K Buy
+42,872
New +$112K ﹤0.01% 896

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Joel Greenblatt's SRNE Position: Q4 2020 in Review

Joel Greenblatt sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 19,928 shares — an estimated $222K sold.

Joel Greenblatt first reported a position in SRNE in Q4 2017 and held it in 5 quarters. The position peaked at $942K in Q2 2018. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Joel Greenblatt reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Joel Greenblatt sold 19,928 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $222K.
  • Joel Greenblatt first reported a position in Sorrento Therapeutics, Inc. in Q4 2017 and held it in 5 quarters.
  • Joel Greenblatt's Sorrento Therapeutics, Inc. position peaked at $942K in Q2 2018.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Gotham Asset Management's 13F filing for Q4 2020, filed 16 Feb 2021.